编者按：2024年美国临床肿瘤学会胃肠道肿瘤研讨会（2024 ASCO Gastrointestinal Cancers Symposium，ASCO GI 2024）将于美国当地时间2024年1月18～20日在旧金山召开。近日ASCO GI官网披露了摘要标题，现整理将于1月18日登场的中国食管胃肿瘤研究，以飨读者。排名不分先后，如有遗漏或错误，欢迎广大读者朋友提醒及指正。
01
口头报告专场
Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.
化疗+卡瑞利珠单抗与单独化疗作为可切除食管鳞状细胞癌的新辅助治疗(ESCORT-NEO):一项多中心，随机III期试验
Presenter: 李印（中国医学科学院肿瘤医院胸外科）
Abstract: LBA244
SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).
SKYSCRAPER-08:一项III期、随机、双盲、安慰剂对照研究，一线(1L)tiragolumab (tira) +阿替利珠单抗(atezo)和化疗(CT)治疗食管鳞状细胞癌(ESCC)患者(pts)
Presenter: Chih-Hung Hsu（中国国立台湾大学医院）
Abstract: 245
02
壁报专场
Trials in Progress Poster Session Level 1, West HallTrials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other Gastrointestinal Cancers
Prospective assessment of adenocarcinoma of esophagogastric junction (AEG) following radical resection: Real-world insights from the CLAEG study.
食管胃交界腺癌根治性切除后的前瞻性评估:来自CLAEG研究的真实世界见解
Presenter: 郑佳彬（广东省人民医院）
Abstract: TPS415
| Poster Bd #: M20
A modified triplet combination of docetaxel, oxaliplatin, and fluorouracil for gastric cancer (GC) with peritoneal carcinomatosis (PC) and inoperable malignant bowel obstruction (MBO): A multi-center, non-randomized, three-cohort, phase II trial (Zhen Jing).
改良的多西紫杉醇、奥沙利铂和氟尿嘧啶三联用药治疗胃癌(GC)合并腹膜癌(PC)和不能手术的恶性肠梗阻(MBO):一项多中心、非随机、三队列、II期试验
Presenter: 肖健（广东省人民医院）
Abstract: TPS426
| Poster Bd #: N11
A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.
一项随机II/III期研究，评估维迪西妥单抗(DV，一款靶向HER2的抗体药物偶联物)联合特瑞普利单抗和化疗/曲妥珠单抗作为一线治疗HER2表达、局部晚期或转移性胃癌的安全性和有效性
Presenter:沈琳（北京大学肿瘤医院）
Abstract: TPS427
| Poster Bd #: N12
Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer.
评价维迪西妥单抗联合信迪利单抗和S-1治疗HER2过表达不可切除胃癌的疗效和安全性的II期临床研究
Presenter: 梁寒（天津医科大学肿瘤医院）
Abstract: TPS428
| Poster Bd #: N13
Prediction of lymph node status in stage T1 esophageal squamous cell carcinoma.
T1期食管鳞状细胞癌淋巴结状态的预测
Presenter: 陈永顺（武汉大学人民医院）
Abstract: 263
| Poster Bd #: C1
Comprehensive molecular characteristics of clinical responses to PD-1 inhibitors plus anti-angiogenic agents (PA) in metastatic HER2-negative gastric adenocarcinoma.
PD-1抑制剂联合抗血管生成药物(PA)治疗转移性HER2阴性胃腺癌临床反应的综合分子特征
Presenter: 王静远（复旦大学附属中山医院）
Abstract: 279
| Poster Bd #: C17
Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer with peritoneal metastasis.
IV期胃癌伴腹膜转移患者免疫检查点抑制剂和化疗后转化治疗后手术的临床疗效
Presenter: Huayuan Liang （南方医科大学南方医院）
Abstract: 281
| Poster Bd #: D1
Design, synthesis, and evaluation of (1E,4E,6E)-1,7-diphenyl hepta-1,4,6-trien-3-one analogues-inspired o-methoxy phenyl group as potential anti–gastric cancer agents.
(1E,4E,6E)-1,7-二苯基庚-1,4,6-三烯-3 -1类似物激发的邻甲氧基苯基潜在抗胃癌药物的设计、合成和评价
Presenter: Fatehi Rashad Abdulwahab Khushafah （温州医科大学）
Abstract: 292
| Poster Bd #: D12
Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: A multicenter, randomized, open-label phase II study.
阿替利珠单抗和曲妥珠单抗联合化疗治疗HER2+局部晚期可切除胃癌或胃食管交界处腺癌:一项多中心、随机、开放标签的II期研究
Presenter: 彭智（北京大学肿瘤医院）
Abstract: 312
| Poster Bd #: E12
A phase Ib/II study of ASKB589 (anti-Claudin 18.2 [CLDN18.2] monoclonal antibody) combined with CAPOX and PD-1 inhibitor as first-line treatment for locally advanced, relapsed and metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma.
ASKB589(抗claudin 18.2 [CLDN18.2]单克隆抗体)联合CAPOX和PD-1抑制剂作为局部晚期、复发和转移性胃/胃食管交界处(G/GEJ)腺癌的一线治疗的Ib/II期研究
Presenter:彭智（北京大学肿瘤医院）
Abstract: 317
| Poster Bd #: E17
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
晚期胃癌、胃食管结合部癌和食管腺癌(GC/GEJC/EAC)患者(pts)一线(1L)纳武利尤单抗(nivolumab)加化疗(chemo) vs化疗:CheckMate 649中国亚组分析，随访4年(yr)
Presenter: 沈琳（北京大学肿瘤医院）
Abstract: 318
| Poster Bd #: E18
Adjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study.
辅助放化疗(CRT) +帕博利珠单抗治疗新辅助CRT +手术后复发风险高的局部晚期食管鳞状细胞癌(ESCC):一项单组II期研究
Presenter: Jhe-Cyuan Guo（国立台湾大学医学院癌医中心医院）
Abstract: 320
| Poster Bd #: E20
A phase 2 study of fruquintinib in combination with S-1 for second-line treatment of esophageal squamous cell carcinoma after first-line immunotherapy failure.
呋喹替尼联合S-1用于一线免疫治疗失败后食管鳞状细胞癌的二线治疗的2期研究
Presenter: 李宁宁（北京协和医院）
Abstract: 323
| Poster Bd #: F3
Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial.
呋喹替尼联合白蛋白紫杉醇治疗免疫检查点抑制剂暴露后晚期G/GEJ癌的疗效和安全性:一项单中心前瞻性临床试验
Presenter: Xiaoting Ma（中国医学科学院肿瘤医院）
Abstract: 327
| Poster Bd #: F7
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023).
替雷利珠单抗联合POFI(伊立替康、紫杉醇、奥沙利铂和5-FU/亚叶酸)作为晚期胃/胃食管交界腺癌(AGC)的一线治疗:单臂、开放标签I/II期试验(SYLT-023)的初步结果
Presenter: 林榕波（福建省肿瘤医院）
Abstract: 331
| Poster Bd #: F11
Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, singlearm, prospective study.
呋喹替尼联合信迪利单抗作为晚期胃和胃食管交界处腺癌(GC/GEJC)的二线治疗:一项单臂、前瞻性II期研究
Presenter: 金敏（华中科技大学同济医学院附属协和医院）
Abstract: 332
| Poster Bd #: F12
A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
呋喹替尼联合SOX和特瑞普利单抗作为晚期转移性胃/胃食管交界处腺癌(GC/GEJC)一线治疗的Ib/II期研究
Presenter: 孟祥瑞（郑州大学第一附属医院）
Abstract: 335
| Poster Bd #: F15
Infusional fluorouracil and weekly docetaxel as first-line therapy for gastric cancer with bone marrow metastasis and disseminated intravascular coagulation: A multi-center, phase II trial (Zhen Long).
输注氟尿嘧啶和每周多西他赛作为胃癌骨髓转移和弥散性血管内凝血的一线治疗:一项多中心II期临床试验(Zhen Long)
Presenter: 肖健（广东省人民医院）
Abstract: 337
| Poster Bd #: F17
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
安罗替尼联合penpuliumab和白蛋白紫杉醇作为晚期食管鳞状细胞癌(ESCC)的一线治疗:一项单组、开放标签的II期临床试验
Presenter: 常志伟（郑州大学第一附属医院）
Abstract: 340
| Poster Bd #: F20
Anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma: A phase II study (ALTER-E005).
安罗替尼联合TQB2450辅助治疗食管鳞状细胞癌:一项II期研究(ALTER-E005)
Presenter: 郭昌莹（江西省肿瘤医院）
Abstract: 347
| Poster Bd #: G8
Neoadjuvant toripalimab plus CapeOX in patients with localized dMMR/MSI-H gastric or esophagogastric junction adenocarcinoma (GC/EGJC): Results from the cohort C of phase II NICE trial.
新辅助特瑞普利单抗加CapeOX治疗局部dMMR/MSI-H胃或食管胃交界腺癌(GC/EGJC):来自II期NICE试验C队列的结果
Presenter: 赵丽瑛（南方医科大学南方医院）
Abstract: 349
| Poster Bd #: G10
Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein–producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.
卡瑞利珠单抗联合阿帕替尼和SOX作为产生甲胎蛋白的胃或胃食管交界处腺癌患者的一线治疗:一项单臂、多中心、2期试验
Presenter: 王雅坤（北京大学肿瘤医院）
Abstract: 351
| Poster Bd #: G12
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
新辅助安罗替尼联合派安普利单抗治疗可切除的局部晚期食管鳞状细胞癌(ESCC):一项前瞻性单组II期试验
Presenter: 陈月云（四川大学华西医院）
Abstract: 352
| Poster Bd #: G13
Preliminary results of surufatinib (Suru) plus standard chemotherapy (ChT) as second line (2L) treatment of advanced gastric cancer (aGC): A single-arm, phase 2 clinical trial.
索凡替尼(Suru)加标准化疗(ChT)作为二线(2L)治疗晚期胃癌(aGC)的初步结果:一项单臂2期临床试验
Presenter: Ting Han（上海交通大学医学院附属仁济医院）
Abstract: 353
| Poster Bd #: G14
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
HLX22 + HLX02和XELOX用于一线治疗HER2阳性局部晚期或转移性胃/胃食管结合部癌:一项随机、双盲、多中心2期研究
Presenter: 李进（同济大学附属东方医院）
Abstract: 354
| Poster Bd #: G15
Surufatinib plus sintilimab in patients with advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, single-center phase II trial.
索凡替尼联合信迪利单抗治疗晚期胃/胃食管交界腺癌(GC/GEJC):一项单臂、开放标签、单中心II期试验
Presenter: 张东生（中山大学肿瘤防治中心）
Abstract: 358
| Poster Bd #: G19
Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge): A single-arm multicenter, phase II trial.
晚期食管鳞状细胞癌患者免疫检查点抑制剂进展后卡瑞利珠单抗加阿帕替尼(CAP 02 Re-challenge)治疗:单组多中心II期试验
Presenter: 孟祥瑞（郑州大学第一附属医院）
Abstract: 364
| Poster Bd #: H6
Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study.
卡瑞利珠单抗联合同步放化疗治疗局部复发食管癌:单臂，开放标签研究
Presenter: 贾瑞诺（河南科技大学第一附属医院）
Abstract: 371
| Poster Bd #: H13
Genomic analysis of oesophageal carcinoma (EC) to identify recurrent mutations in histone methyltransferases as a distinctive subset.
食管癌(EC)的基因组分析，以确定组蛋白甲基转移酶的复发突变作为一个独特的子集
Presenter: 王静远（复旦大学附属中山医院）
Abstract: 379
| Poster Bd #: J2
Detection of early-stage gastrointestinal cancers by micronuclei DNA from erythrocytes.
红细胞微核DNA检测早期胃肠道癌
Presenter: 孙浩博（西湖大学）
Abstract: 382
| Poster Bd #: J5
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).
三种程序性死亡配体1 (PD-L1)评分方法的一致性及其与替雷利珠单抗(TIS)单药治疗食管鳞状细胞癌(ESCC)临床结果的相关性
Presenter: 束永前（南京医科大学第一附属医院）
Abstract: 390
| Poster Bd #: J13
Unveiling prognosis and traits of dMMR/MSI-H gastric and colorectal cancer after curative surgery: A large-scale, multi-center, retrospective study in China.
揭示dMMR/MSI-H胃癌和结直肠癌根治性手术后的预后和特征:中国一项大规模、多中心、回顾性研究
Liquid biopsy-based comprehensive genomic profiling to reveal mutational landscape in real-world patients with gastrointestinal cancer.
液体活检为基础的全面基因组分析揭示真实世界的胃肠道癌症患者突变情况
Presenter: Haoran Tang（慧渡（上海）医疗科技有限公司）
Abstract: 735
| Poster Bd #: L10
Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.
安洛替尼治疗中国肝脏转移性胃肠道肿瘤的真实世界数据
Presenter: 祝喻甲（中山大学肿瘤防治中心）
Abstract: 738
| Poster Bd #: L13
Multicenter clinical validation of GutSeer: A cost-effective, blood-based assay for early detection and localization of major gastrointestinal cancers.
GutSeer的多中心临床验证:一种具有成本效益的血液检测方法，用于主要胃肠道癌症的早期检测和定位
Presenter: 陈万青（中国医学科学院肿瘤医院）
Abstract: 739
| Poster Bd #: L14
Is lymph node metastasis an event indicating an advanced gastrointestinal stromal tumor?
淋巴结转移是晚期胃肠道间质瘤的标志吗?
Presenter: 张鹏（武汉协和医院）
Abstract: 754
| Poster Bd #: M9